Centessa Pharmaceuticals plc American Depositary Shares (CNTA) is a publicly traded Healthcare sector company. As of August 25, 2026, CNTA trades at $40.50 with a market cap of $6.27B and a P/E ratio of -27.74. CNTA moved +0.93% today. Year to date, CNTA is +68.89%; over the trailing twelve months it is +211.54%. Its 52-week range spans $9.60 to $40.56. Analyst consensus is neutral with an average price target of $43.50. Rallies surfaces CNTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
High Court Approves Lilly’s $7.8B Deal to Buy Centessa for $38 Plus $9 CVR: On June 22, the High Court of Justice of England and Wales sanctioned Lilly’s acquisition of Centessa for $38 per share and one CVR worth up to $9. The $7.8 billion transaction will close upon delivery to the Registrar on June 24, with ADS trading halted before market open that day.
| Metric | Value |
|---|---|
| Price | $40.50 |
| Market Cap | $6.27B |
| P/E Ratio | -27.74 |
| EPS | $-1.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.56 |
| 52-Week Low | $9.60 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $15.00M |
| Net Income | $-197.53M |
| Gross Margin | 0.00% |
9 analysts cover CNTA: 0 strong buy, 1 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $43.50.